CNS inflammation after natalizumab therapy for multiple sclerosis: A retrospective histopathological and CSF cohort study

Natalizumab, a recombinant humanized monoclonal antibody directed against the α4 subunit of the integrins α4ß1 and α4ß7, has been approved for the treatment of active relapsing‐remitting MS. Although natalizumab is a highly beneficial drug that effectively reduces the risk of sustained disability pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Häusler, Darius, Akgün, Katja, Stork, Lidia, Lassmann, Hans, Ziemssen, Tjalf, Brück, Wolfgang, Metz, Imke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8549024/
https://www.ncbi.nlm.nih.gov/pubmed/33955606
http://dx.doi.org/10.1111/bpa.12969

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8549024/
https://www.ncbi.nlm.nih.gov/pubmed/33955606
http://dx.doi.org/10.1111/bpa.12969

Ejemplares similares